Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin Maximilian Awad

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
International Review of Cell and Molecular Biology|January 15, 2024
Novel technologies for applying immune checkpoint blockersRobin Maximilian Awad, Karine Breckpot
Frontiers in Immunology|September 21, 2018
Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer ProgressionRobin Maximilian Awad, Yannick De Vlaeminck, Johannes Maebe, et al.
Pharmaceuticals (Basel, Switzerland)|July 2, 2021
Site-Specific Radiolabeling of a Human PD-L1 Nanobody via Maleimide-Cysteine ChemistryDora Mugoli Chigoho, Quentin Lecocq, Robin Maximilian Awad, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|January 21, 2024
Sustained release of a human PD-L1 single-domain antibody using peptide-based hydrogelsJulie Heremans, Robin Maximilian Awad, Jessica Bridoux, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 13, 2021
Single-Domain Antibody Nuclear Imaging Allows Noninvasive Quantification of LAG-3 Expression by Tumor-Infiltrating Leukocytes and Predicts Response of Immune Checkpoint BlockadeQuentin Lecocq, Robin Maximilian Awad, Yannick De Vlaeminck, et al.
Frontiers in Immunology|October 6, 2023
Development and evaluation of nanobody tracers for noninvasive nuclear imaging of the immune-checkpoint TIGITKatty Zeven, Timo W M De Groof, Hannelore Ceuppens, et al.
Scientific Reports|November 4, 2023
In vitro modelling of local gene therapy with IL-15/IL-15Rα and a PD-L1 antagonist in melanoma reveals an interplay between NK cells and CD4<sup>+</sup> T cellsRobin Maximilian Awad, Yannick De Vlaeminck, Fien Meeus, et al.
Journal for Immunotherapy of Cancer|November 19, 2024
Preclinical evaluation of antigen-sensitive B7-H3-targeting nanobody-based CAR-T cells in glioblastoma cautions for on-target, off-tumor toxicityFien Meeus, Cyprine Neba Funeh, Robin Maximilian Awad, et al.
Molecular Cancer Therapeutics|May 2, 2022
Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177-Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma ModelThomas Ertveldt, Lien De Beck, Kirsten De Ridder, et al.
Cancers|December 3, 2020
Targeting Neuropilin-1 with Nanobodies Reduces Colorectal Carcinoma DevelopmentYannick De De Vlaeminck, Stefano Bonelli, Robin Maximilian Awad, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
International Review of Cell and Molecular Biology|January 15, 2024
Novel technologies for applying immune checkpoint blockersRobin Maximilian Awad, Karine Breckpot
Frontiers in Immunology|September 21, 2018
Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer ProgressionRobin Maximilian Awad, Yannick De Vlaeminck, Johannes Maebe, et al.
Pharmaceuticals (Basel, Switzerland)|July 2, 2021
Site-Specific Radiolabeling of a Human PD-L1 Nanobody via Maleimide-Cysteine ChemistryDora Mugoli Chigoho, Quentin Lecocq, Robin Maximilian Awad, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|January 21, 2024
Sustained release of a human PD-L1 single-domain antibody using peptide-based hydrogelsJulie Heremans, Robin Maximilian Awad, Jessica Bridoux, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 13, 2021
Single-Domain Antibody Nuclear Imaging Allows Noninvasive Quantification of LAG-3 Expression by Tumor-Infiltrating Leukocytes and Predicts Response of Immune Checkpoint BlockadeQuentin Lecocq, Robin Maximilian Awad, Yannick De Vlaeminck, et al.
Frontiers in Immunology|October 6, 2023
Development and evaluation of nanobody tracers for noninvasive nuclear imaging of the immune-checkpoint TIGITKatty Zeven, Timo W M De Groof, Hannelore Ceuppens, et al.
Scientific Reports|November 4, 2023
In vitro modelling of local gene therapy with IL-15/IL-15Rα and a PD-L1 antagonist in melanoma reveals an interplay between NK cells and CD4<sup>+</sup> T cellsRobin Maximilian Awad, Yannick De Vlaeminck, Fien Meeus, et al.
Journal for Immunotherapy of Cancer|November 19, 2024
Preclinical evaluation of antigen-sensitive B7-H3-targeting nanobody-based CAR-T cells in glioblastoma cautions for on-target, off-tumor toxicityFien Meeus, Cyprine Neba Funeh, Robin Maximilian Awad, et al.
Molecular Cancer Therapeutics|May 2, 2022
Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177-Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma ModelThomas Ertveldt, Lien De Beck, Kirsten De Ridder, et al.
Cancers|December 3, 2020
Targeting Neuropilin-1 with Nanobodies Reduces Colorectal Carcinoma DevelopmentYannick De De Vlaeminck, Stefano Bonelli, Robin Maximilian Awad, et al.
Pageof 2